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The induction and modulation of the immune response to vaccination can be ratio-
nally designed by combining different vaccine formulations for priming and boost-
ing. Here, we investigated the impact of heterologous prime-boost approaches on 
the vaccine-specific cellular and humoral responses specific for a mycobacterial 
vaccine antigen. C57BL/6 mice were primed with the chimeric vaccine antigen H56 
administered alone or with the CAF01 adjuvant, and boosted with H56 alone, or 
combined with CAF01 or with the squalene-based oil-in-water emulsion adjuvant 
(o/w squalene). A strong secondary H56-specific CD4+ T cell response was recalled 
by all the booster vaccine formulations when mice had been primed with H56 and 
CAF01, but not with H56 alone. The polyfunctional nature of T helper cells was ana-
lyzed and visualized with the multidimensional flow cytometry FlowSOM software, 
implemented as a package of the R environment. A similar cytokine profile was 
detected in groups primed with H56 + CAF01 and boosted with or without adjuvant, 
except for some clusters of cells expressing high level of IL-17 together with TNF-α, 
IL-2, and IFN-γ, that were significantly upregulated only in groups boosted with the 
adjuvants. On the contrary, the comparison between groups primed with or without 
the adjuvant showed a completely different clusterization of cells, strengthening the 
impact of the formulation used for primary immunization on the profiling of respond-
ing cells. The presence of the CAF01 adjuvant in the priming formulation deeply 
affected also the secondary humoral response, especially in groups boosted with 
H56 alone or o/w squalene. In conclusion, the presence of CAF01 adjuvant in the 
primary immunization is crucial for promoting primary T and B cell responses that 
can be efficiently reactivated by booster immunization also performed with antigen 
alone.
Keywords: prime-boost regimens, adjuvants, computational flow cytometry, T  cells, intracellular cytokines, 
caF01, priming
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inTrODUcTiOn
A key aspect for the generation of efficacious vaccines is the 
optimization of vaccine schedules capable of eliciting the more 
adequate immune response for a specific pathogen, balancing 
between humoral and cell-mediated immunity. The design of 
prime-boost vaccine combinations based on the selection of 
the vaccine formulation, the dose, the route, and the intervals 
between doses is therefore of critical importance for optimally 
shaping the immune response.
With the exception of very few antigens, such as certain toxins, 
almost all the purified proteins used as vaccine antigens gener-
ally induce a modest antibody response with little or no T cell 
response (1). Adjuvants have proven to be key components in 
vaccines, providing danger signals and triggering a sufficient 
activation of the innate system. The presence of the adjuvant 
allows to enhance and appropriately skew the immune responses 
toward a vaccine antigen (1, 2) and promotes the induction of 
long-lived immunological memory and protection. Profiling the 
mode of action of different adjuvants is of critical importance for 
the rationale design of vaccination strategies (3–5). One of the 
immunological events that play a pivotal role in the generation 
of a vaccine-specific immune response is the primary activation 
of T helper cells, due to its close relationship with long-term 
humoral immunity and induction of protective antibodies (6). 
Antigen-specific T helper clonal expansion, differentiation, and 
dissemination toward distal sites are regulated by different fac-
tors, such as the route of the primary immunization, the dose of 
the antigen, and the vaccine formulations (7–15). We have dem-
onstrated that an efficient antigen-specific CD4+ T cell priming, 
generating cells capable of responding to booster immunization, 
is preferentially elicited by the subcutaneous, and not by the nasal 
route of immunization (3). Nevertheless, the nasal route can be 
efficiently used for booster immunization, when a local effector 
cellular response is aimed, since it promotes the recruitment of 
activated T cells into the lungs (3). Mathematical models can be 
used as a tool to estimate in vivo the probability of antigen-specific 
CD4+ T  cell expansion and dissemination upon immunization 
with adjuvanted vaccine formulations (16). Clonally expanded 
CD4+ T  cells exert the effector function producing cytokines. 
On the basis of the simultaneous expression of specific pattern of 
cytokines, Th cells are classified into functionally defined effector 
subpopulations. This fate is strongly affected by factors such as 
the local pro-inflammatory environment, the dose and the route 
of the vaccine used, and the adjuvant included in the vaccine 
formulation (17, 18).
Since the priming event impacts the type and quality of the 
induced immune response, we have recently characterized the 
mode of action of four different adjuvants, alum, a squalene-
based oil-in-water emulsion (structurally similar to the licensed 
MF59 adjuvant), CpG ODN1826 (19), and the liposome system 
CAF01 (20), after a single immunization (4). Comparative analy-
sis showed that CAF01 and o/w squalene were the strongest adju-
vants capable of activating cellular response, with a Th1/Th2 and 
Th1/Th17 profile, respectively. O/w squalene rapidly induced the 
release of antigen-specific IgG in serum while CAF01 stimulated 
the germinal center (GC) reaction within the draining lymph 
nodes. A strong GC reaction was also observed in the presence of 
alum, even if an early humoral response was not detected. On the 
contrary, CpG ODN adjuvant elicited a rapid humoral response, 
but not a CD4+ T cell activation and only a mild GC reaction, 
suggesting a T-independent activation of the B cell response, due 
to the direct stimulation of TLRs on B cells (21). With these infor-
mation, rationale combination of adjuvants can be exploited for 
designing vaccination approaches capable of eliciting the most 
adequate immune response for a specific pathogen. The strategy 
of generating a toolbox of adjuvants, with a well-defined profile to 
shape the immune response, has also been recently identified as a 
key priority in vaccine research and development in Europe1 (22).
When many parameters are combined in a flow cytometric 
analysis for studying the phenotype, the effector function, and 
the polyfunctionality of activated cells, as is the case of the 
characterization of an immune response elicited by vaccination, 
classical two-dimensional scatter plots analysis cannot be suf-
ficient for the multidimensional nature of the data. To overcome 
this problem, novel computational techniques have been devel-
oped in the recent years, and computational flow cytometry has 
become a novel discipline useful for providing a set of tools to 
analyze, visualize, and interpret large amounts of cell data in a 
more automated and unbiased way (23). FlowSOM is an advanced 
visualization technique in which more information are provided 
than in the traditional two-dimensional scatter plots (24). A 
self-organizing map (SOM) is an unsupervised technique for 
clustering and dimensionality reduction, in which a discretized 
representation of the input space is trained. With FlowSOM, cells 
are grouped into cell type clusters that are then represented in 
a lower-dimensional space. This approach allows to visualize in 
the same picture information regarding the frequency of cells co-
expressing different markers, and to compare different groups.
In this work, we have assessed different prime-boost combina-
tions, using the CAF01 and o/w squalene adjuvants, in order to 
dissect their role in shaping the secondary immune response to 
the chimeric vaccine antigen H56, a promising vaccine candidate 
against Mycobacterium tuberculosis, consisting of the antigens 
Ag85B fused to the 6-kDa early secretory antigenic target and 
the latency-associated protein Rv2660c (25), already tested in 
four phase I and II clinical trials.2 The analysis of the serum IgG 
strength of binding to the vaccine antigen performed by surface 
plasmon resonance, and the computational analysis of the poly-
functional nature of reactivated CD4+ T cells, have been used to 
highligh the impact of the priming event in the induction of the 
adaptive immune response.
MaTerials anD MeThODs
Mice
Seven-week-old female C57BL/6 mice, purchased from 
Charles River (Lecco, Italy), were housed under specific path-
ogen-free conditions in the animal facility of the Laboratory 
of Molecular Microbiology and Biotechnology, Department of 
1 www.iprove-roadmap.eu.
2 http://ClinicalTrials.gov.
FigUre 1 | Study design and sample collection. Groups of C57BL/6 mice 
were subcutaneously primed with H56 alone (H56) or combined with CAF01, 
and boosted at day 28 with H56 + CAF01, or H56 + o/w squalene or H56 
alone. Blood samples were collected at day 0, 12, 28, 31, and 38 following 
priming; draining lymph nodes (dLN) and spleens (Spl) were collected at day 
7, 28, 31, and 38. The abbreviations of the different prime-boost 
combinations are here reported and used in all the figures.
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Medical Biotechnologies at University of Siena. This study was 
carried out in accordance with national guidelines (Decreto 
Legislativo 26/2014). The protocol was approved by the 
Italian Ministry of Health (authorization no. 1004/2015-PR, 
22 September 2015).
immunizations
Mice were immunized by the subcutaneous route at the base 
of the tail, with vaccine formulations including the chimeric 
tuberculosis vaccine antigen H56 (2  μg/mouse for priming, 
0.5 μg/mouse for boosting; Statens Serum Institut, Denmark), 
administered alone or combined with the adjuvants CAF01 
(250  µg dimethyldioctadecylammonium and 50  µg trehalose 
dibehenate/mouse; Statens Serum Institut, Denmark), or a 
squalene-based oil-in-water adjuvant [50  μl/mouse, sorbitan 
trioleate (0.5% w/v) in squalene oil (5% v/v), and Tween 80 (0.5% 
w/v) in sodium citrate buffer (10 mM, pH 6.5), Invivogen, USA]. 
Groups of five mice were primed with H56 or H56 +  CAF01 
and boosted with H56, H56 + CAF01, or H56 + o/w squalene, 
4 weeks later, as reported in Figure 1. Formulations containing 
CAF01 were injected in a volume of 150 μl/mouse of Tris 10 mM, 
while formulations containing o/w squalene or H56 alone in a 
volume of 100 μl/mouse of PBS. Groups of mice were sacrificed 
7 and 28  days after priming, and 3 or 10  days after boosting 
(Figure 1).
sample collection and cell Preparation
Blood samples were taken from the temporal plexus of mice 0, 
12, and 28 days after priming and 3 and 10 days after boosting. 
Samples were incubated for 30 min at 37°C and centrifuged at 
1,200 × g at 4°C for 10 min for collecting sera that were stored at 
−80°C. Draining lymph nodes (sub iliac, medial, and external) 
and spleens were collected 7 and 28 days after priming, and 3 or 
10 days after boosting. Samples were mashed onto 70 µm nylon 
screens (Sefar Italia, Italy) and washed two times in complete 
RPMI medium [RPMI (Lonza, Belgium), 100  U/ml penicillin/
streptomycin, and 10% fetal bovine serum (Gibco, USA)]. 
Samples were treated with red blood cells lysis buffer (eBiosci-
ence, USA) and counted with cell counter (Bio-Rad).
Multiparametric Flow cytometric analysis
Samples from draining lymph nodes (dLN) and spleens 
were incubated for 30  min at 4°C in Fc-blocking solution 
(cRPMI with 5  µg/ml of CD16/CD32 mAb [clone 93; eBiosci-
ence, USA]). Cells from dLN were stained for 1  h at RT with 
PE-conjugated I-A(b) M. tuberculosis Ag85B precursor 280–294 
(FQDAYNAAGGHNAVF) tetramer (kindly provided by NIH 
MHC Tetramer Core Facility, Emory University, Atlanta, GA, 
USA), washed and surface stained with HV500-conjugated anti-
CD4 (clone RM4-5; BD Biosciences) and BV786-conjugated 
anti-CD44 (clone IM-7; BD Biosciences). Samples were labeled 
with Live/Dead Fixable Near-IR Stain Kit according to the manu-
facturer instruction (Invitrogen, USA). Intracellular cytokine 
production was assessed on splenocytes cultured for 6 h in the 
presence of anti-CD28, anti-CD49d (both 2 µg/ml, eBioscience), 
and H56 protein (2 µg/ml). Unstimulated or PMA and ionomycin 
calcium salt (50  ng/ml and 1  µM respectively, Sigma-Aldrich) 
treated cells were used as negative and positive controls, respec-
tively. Brefeldin A (BFA, 5 µg/ml, Sigma-Aldrich) and monensin 
solution (1×, eBioscience) were added to all samples for the last 
4 h of incubation. Cells were washed twice in PBS and labeled with 
Live/Dead Fixable Yellow Stain Kit according to the manufacturer 
instruction (Invitrogen, USA). Fixation and permeabilization 
were performed using BD Cytofix/Cytoperm kit according to the 
manufacturer instruction (BD Biosciences) before Fc-blocking 
and stained with HV500-conjugated anti-CD4 (clone RM4-5; 
BD Biosciences), BV786-conjugated anti-CD44 (clone IM-7; 
BD Biosciences), PerCP Cy5.5-conjugated anti-IFN-γ (clone 
XMG1.2; BD Biosciences), AF700-conjugated anti-TNF-α (clone 
MP6-XT22; BD Biosciences), APC-conjugated anti-IL-17A 
(clone eBio17B7; eBioscience), AF488-conjugated anti-IL-4 
(clone 11B11; eBioscience), AF488-conjugated anti-IL-13 (clone 
eBio13A; eBioscience). All antibodies and tetramers were titrated 
for optimal dilution. About 5–10 × 105 cells were stored for each 
sample, and acquired on BD LSRFortessa X20 flow cytometer 
(BD Biosciences). Data analysis was performed using FlowJo v10 
(TreeStar, USA).
computation analysis of Flow cytometric 
Data with FlowsOM
Data from restimulated splenocytes were first analyzed with FlowJo. 
Live lymphocytes expressing CD4 and CD44 were manually gated, 
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concatenated within the same immunization group, randomly 
downsampled to 15,000 cells and exported as uncompensated 
cells. Data were then compensated, logically transformed and 
scaled with FlowSOM (24). FlowSOM is a package of R, an open-
source environment for statistical analysis, computation, and 
visualization,3 available as a Bioconductor package. Clustering 
analysis of data was performed following the FlowSOM function 
pipeline. The algorithm considers each cell in an n-dimensional 
space (where n =  the number of cytokines considered for the 
analysis); cells with similar position in n-dimensional space are 
clustered together. After clustering, a SOM is built, where all 
clusters represent nodes and the nodes closely connected to each 
other resemble each other more than nodes that are only con-
nected through a long path. The resulting clustering of the SOM is 
visualized in a minimal spanning tree. Three different sets of FCS 
files, named flowSet, were analyzed: (a) FCS files from the groups 
primed with H56 + CAF01 and boosted with H56, H56 + CAF01, 
and H56 + o/w squalene, (b) groups primed with H56 + CAF01 or 
H56 alone and boosted with H56 + CAF01, and (c) groups primed 
with H56 + CAF01 or H56 alone and boosted with H56 + o/w 
squalene. For each flowSet, a SOM (function “FlowSOM”) was 
built. Functions “CountGroups” and “PlotGroups” were used to 
visualize the flowSets as minimal spanning tree, to color the nodes 
depending on the expression of five cytokines and to highlight 
changes higher than twofold in each node.
enzyme-linked immunosorbent  
assay (elisa)
Serum H56-specific IgG were determined by ELISA. Flat bottomed 
Maxisorp microtiter plates (Nunc, Denmark) were coated with 
H56 (0.5 µg/ml) for 3 h at 37°C and overnight at 4°C in a volume 
of 100 µl/well. Plates were washed and blocked with 200 µl/well of 
PBS containing 1% BSA (Sigma-Aldrich) for 2 h at 37°C. Serum 
samples were added and titrated in twofold dilution in duplicate 
in PBS supplemented with 0.05% Tween 20 and 0.1% BSA (diluent 
buffer) in 100 µl/well. After 2 h at 37°C, samples were incubated 
with the alkaline phosphatase-conjugate goat anti-mouse IgG 
(diluted 1:1,000 in diluent buffer, Southern Biotechnology, USA) 
for 2 h at 37°C in 100 µl/well and developed by adding 1 mg/ml 
of alkaline phosphatase substrate (Sigma-Aldrich) in 200 µl/well. 
The optical density was recorded using Multiskan FC Microplate 
Photometer (Thermo Scientific). Antibody titers were expressed 
as the reciprocal of the highest serum dilution with an OD value 
≥0.2, after subtraction of background values measured with dilu-
ent buffer alone.
Binding of anti-h56 antibodies by  
surface Plasmon resonances
H56 antigen was immobilized on CM4 sensor chip (GE 
Healthcare) following standard amine coupling procedures. 
Antigen diluted at the concentration of 25  µg/ml in sodium 
acetate pH 3.5 was injected for 300 s at the flow rate of 5 µl/min 
over the sensor chip surface, previously activated with a 1:1 
mixture of EDC-NHS. After immobilization, ethanolamine-HCl 
3 www.r-project.org.
was injected for 7 min over all the surface to block any remaining 
active site on sensor chip surface. A blank immobilization was 
performed for the reference flow cell. Sera were diluted 200-fold 
in HBS-EP+ (10 mM Hepes, 150 mM NaCl, 3.4 M EDTA, 0.05% 
polysorbate 20, pH 7.4) and injected for 180 s at a flow rate of 
30  µl/min onto immobilized H56, and dissociation phase was 
allowed for 300 s. Surface regeneration was achieved with a 45-s 
pulse of 10 mM glycine pH 2.0 at the same flow rate. For anti-
body isotyping, serum samples diluted 1:200 in HBS-EP+ were 
injected for 180 s across the H56-immobilized surface at 30 µl/
min, allowing sample binding to the surface. Then anti-mouse 
IgM and anti-mouse IgG antibodies, respectively, diluted 1:250 
and 1:500 in HBS-EP+ were sequentially injected for 120 s each at 
30 µl/min. For anti-H56 monoclonal antibody binding, Hyb76-8 
was diluted at different concentrations (40, 20, 10, 5, 2.5, 1, and 
0.5 µg/ml) in HBS-EP+ and then injected for 180 s at the flow rate 
of 30 µl/min onto immobilized H56, and dissociation phase was 
allowed for 450 s. Surface regeneration was achieved with a 30-s 
pulse of 10 mM glycine pH 2.0 at 30 µl/min.
The experiments were performed on a Biacore T100 instru-
ment (GE Healthcare). The actual binding response of samples 
(RU) was obtained by subtracting the background response, 
recorded by injecting the sample through the reference flow cell. 
Kinetic of anti-H56 mAb was analyzed with the “Biacore T100 
evaluation 1.1.1” software using the 1:1 Langmuir model for 
fitting the curves. Dissociation rates were calculated by curve-
fitting analysis to a dissociation model.
statistical analysis
Mann–Whitney test for multiple pairwise comparisons was 
used for assessing statistical difference between groups receiving 
the same booster and primed with H56 alone or H56 + CAF01 
adjuvant. Kruskal–Wallis test, followed by Dunn’s post test for 
multiple comparison, was used to assess statistical difference 
among all groups. IgG titers were reported as geometric mean 
titers (GMT) with 95% CI, and statistical analysis was performed 
on log-transformed data. Statistical significance was defined 
as P ≤ 0.05. Analysis was performed using GraphPad Prism v7 
(GraphPad Software, USA).
resUlTs
Primary ag-specific cD4+ T cell 
expansion and effector Function
Groups of mice were parenterally primed with the chimeric 
tuberculosis vaccine antigen H56 administered alone or com-
bined with the liposome system CAF01. Four weeks later, mice 
were boosted with three different formulations: the H56 antigen 
alone, the H56 antigen combined with CAF01, or mixed with 
an oil-in-water (o/w) squalene-based emulsion, hereafter o/w 
squalene (Figure  1). The induction of antigen-specific CD4+ 
T cell expansion into the draining iliac lymph nodes was assessed 
7 and 28 days after priming, and 3 and 10 days after booster immu-
nization. Antigen-specific CD4+ T  cells were identified using 
Ag85B280–294-complexed MHC class II tetramers, specific for the 
immunodominant epitope of Ag85B, that is part of the chimeric 
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intensity (MFI) values of each cytokine are visualized inside each 
node. The height of each sector indicates the intensity, therefore 
when it reaches the border of the circle, this indicates that these 
cells have a high expression for that cytokine. The co-expression 
FigUre 2 | Ag85B-specific CD4+ T cell response. C57BL/6 mice were 
subcutaneously immunized as summarized in Figure 1. Draining lymph 
nodes were collected 7 and 28 days after priming, and 3 and 10 days after 
booster immunization and analyzed for the frequency of Ag-specific CD4+ 
T cells, identified by staining with Ag85B-specific MHC class II tetramers 
(Tet-Ag85B). (a) Scatter plot of CD44 versus Tet-Ag85B, gated on live 
CD4+ lymphocytes, shown from a single animal representative of each 
immunization group, collected 10 days after boosting. Activated tetramer+ 
cells are gated and the frequency reported. (B) Time course analysis of the 
frequencies of tetramer+ CD4+ T cells, detected in each group, reported as 
mean ± SEM of five mice per group. Mann–Whitney test for multiple 
pairwise comparisons was used for assessing statistical difference between 
groups receiving the same booster and primed with H56 alone or 
H56 + CAF01 adjuvant. Kruskal–Wallis test, followed by Dunn’s post test 
for multiple comparison, was used to assess statistical difference among all 
groups (P ≤ 0.05).
H56 protein. Staining specificity was determined using a control 
tetramer complexed with an unrelated antigen that showed a 
level of staining below 0.02% (data not shown). Representative 
dot plots showing the frequencies of tetramer-positive (Tet+) 
T  cells elicited by the different vaccine formulations 10 days 
after boosting are shown in Figure 2A. As clearly observed, all 
the groups primed with the vaccine formulation containing the 
CAF01 adjuvant, developed a recall response of the CD4+ T cells 
significantly higher compared to groups primed with H56 antigen 
alone (Figure 2B, P ≤  0.05). The frequency of antigen-specific 
CD4+ T cells was higher in mice primed with H56 + CAF01 and 
boosted with H56 + o/w squalene versus all groups primed with 
H56 (P ≤  0.05) while no significant differences were observed 
versus groups boosted with H56 alone or H56 + CAF01 (CAF/
H56 and CAF/CAF). The secondary response clearly reflects the 
reactivation of cells activated by the primary immunization with 
H56 + CAF01, observed 7 days after priming (Figure 2B).
Since most of T helper cells activated into the draining lymph 
nodes exit and recirculate, the effector function of H56-specific 
CD4+ T cells was assessed in the spleen, analyzing the intracellular 
production of different cytokines using multicolor flow cytom-
etry. Dot plots, representative of the different groups, showing 
the frequencies of H56-specific CD4+ T cells producing TNF-α, 
IFN-γ, IL-17, or IL-4/IL-13 cytokines versus IL-2, a cytokine 
indicative of the proliferative response and activation program of 
antigen-specific T cells, are reported in Figure 3A. The analysis 
of the effector function clearly confirmed the importance of the 
priming event to elicit cells capable of reactivation upon antigen 
restimulation. Indeed, only groups of mice that had been primed 
with H56 + CAF01 were able to reactivate, upon boosting, cells 
co-expressing IL-2 with TNF-a (55%, 38%, and 31% in CAF/
SQL, CAF/H56, and CAF/CAF groups, respectively), with IFN-γ 
(47%, 32%, and 30%, respectively) or with IL-17 (9%, 3%, and 6%, 
respectively), with percentages of effector cells significantly higher 
compared to the respective groups primed with H56 (Figure 3B; 
Mann–Whitney test for multiple pairwise comparisons, P ≤ 0.05). 
Interestingly, the booster immunization with o/w squalene, an 
adjuvant capable of stimulating a primary Th1 and Th2 mixed 
response (4), increased the frequency of cells releasing IL-2 with 
IL4 and IL13 (7%; P ≤  0.05 versus the respective group H56/
SQL), even though these cytokines were not observed following 
priming with H56 + CAF01 (Figure 3B). It was also clearly shown 
that mice primed with H56 alone did not respond to the booster 
immunization, also when CAF01 or o/w squalene adjuvants were 
used (Figure 3B).
computational analysis of intracellular 
cytokines Production
In order to have a global picture of the polyfunctional profiles of 
T cells elicited by the different vaccine formulations, a computa-
tional analysis of data was performed using the multidimensional 
software FlowSOM. A minimal spanning tree was built connect-
ing the nodes that were most similar to each other in minimal 
branches. Each cell was then classified to the nearest node that 
was coded as a pie chart with information about the expression 
of the five different cytokines (Figure 4). The mean fluorescence 
6Ciabattini et al. Adjuvant Role in Prime-Boost Vaccination
Frontiers in Immunology | www.frontiersin.org March 2018 | Volume 9 | Article 380
intensity of more cytokines by a group of cells clustered into the 
same node can be easily visualized. Moreover, the size of the 
nodes indicates the number of cells assigned to each node, so it 
is indicative of the frequency of activated CD4+ T cells expressing 
that pattern of cytokines.
Trees obtained in the groups primed with H56 + CAF01 and 
boosted with H56 + CAF01 (CAF/CAF) or H56 + o/w squalene 
(CAF/SQL) are shown in Figures 4A,B, respectively. Forty nine 
nodes were created by the FlowSOM algorithm. The upper 
half of the trees shows nodes co-expressing more cytokines, in 
particular TNF-α, IL-2, and IFN-γ, with a high MFI. On the 
contrary, cells expressing very few cytokines with low MFI are 
shown in the lower half of the tree. When the frequency of cells 
within a node increased or decreased by at least twofold with 
respect to mice boosted with H56 alone, nodes were colored in 
blue or pink, respectively (Figures  4A,B). Mice boosted with 
CAF01 increased the frequency of cells expressing the pattern 
of cytokines shown in nodes 6, 7, 14 (upper half of the tree), and 
10, 16, 41, 48 and 49 (lower half of the tree). Nodes 6, 7, and 14 
include cells with a high expression of IL-17 together with TNF- α, 
IL-2 (node 7), and also IFN-γ (nodes 6 and 14) as shown in the 
magnification reported on the right of Figure  4A. The other 
nodes (10, 16, 41, 48, and 49) include cells with a weak expression 
of some cytokines, as indicated by the height of the sectors. At the 
same time, CAF01 induced the reduction of nodes 4, 11, and 33 
(pink), which express TNF-α, IL-2 (nodes 11 and 33), and also 
IFN-γ (node 4). Interestingly, the cluster of cells co-expressing 
IL-17 (nodes 6, 7, and 14) was significantly increased also with 
o/w squalene with respect to H56 alone (Figure 4B). The amount 
of cells co-expressing TNF- α, IL-2, IFN-γ with an intermedi-
ate MFI of IL-4/IL-13 (nodes 1, 27, and 28) was also increased 
(Figure 4B). The frequency of cells clustered within single nodes 
for each immunization schedule is reported in Figure 5. Here, 
we can observe how many nodes the two plotted groups have in 
common, with a similar percentage of cells clustered inside (black 
dots), and how many nodes include an amount of cells ≥2-fold 
with respect to the compared immunization group (colored dots). 
In Figure 5 panels A and B, the comparison of FlowSOM cluster-
ing between groups primed with H56 + CAF01 and boosted with 
adjuvanted formulations or H56 alone is reported, reflecting the 
differences shown in Figure 4. Panels C and D show the com-
parison between groups receiving different priming (H56 alone 
or with CAF01) but boosted with the same formulation (either 
H56 + CAF or H56 + o/w squalene). In this case, the amount of 
common nodes between the compared formulations drastically 
diminished while more than 40 nodes were differently clustered 
among compared groups (Figures 5C,D).
As a whole, we can conclude that there are some clusters of 
cells, mainly oriented toward the secretion of IL-17 together with 
other cytokines, that significantly increase due to the presence 
of the adjuvants in the booster immunization, while the rest of 
the nodes do not significantly change between different boosting 
formulations. On the contrary, a drastical change of most of the 
nodes is observed comparing groups receiving a priming with or 
without the adjuvant, confirming again that the priming setting 
defines the generation of cells capable of secondary reactivation. 
The overall CD4+ T cell response analysis clearly underlines the 
different roles of the priming and boosting events with respect to 
the adaptive immune response.
humoral immune response
The induction of antigen-specific IgG antibody response was 
assessed at different time points after priming and boosting 
(Figure 1). The primary response elicited by both H56 alone or 
combined with CAF01 was very similar at 12 and 28 days after 
priming, while the secondary IgG response showed significant 
differences according to the formulation used for the booster 
immunization (Figure 6). Mice primed with H56 + CAF01 and 
boosted with H56 + o/w squalene, or with H56 alone developed 
the highest humoral response compared to all the other groups 
(P ≤ 0.05 of CAF/H56 versus H56/CAF). A significant difference 
was also detected between the two groups boosted with H56 
alone but differently primed (P ≤ 0.05), indicating that a consist-
ent recall antibody response can be elicited also by the antigen 
alone when an efficient priming had been performed.
Using surface plasmon resonance, we further compared 
sera collected after boosting for the capacity of binding to H56 
immobilized on the sensor chip surface and data were expressed 
as resonance units (RU). The antibody isotype characterization 
indicated a complete absence of IgM in all the analyzed samples, 
thus allowing to correlate RU with IgG concentration (Figure S1 
in Supplementary Material). Sensorgrams from single animals 
primed with or without the adjuvant and boosted with the same 
vaccine formulations showed higher binding responses to H56 in 
groups that had received a primary immunization with CAF01, 
compared to sera from mice primed with H56 alone (Figure 7A). 
The mean values of RU calculated for each immunization group 
are reported in Figure 7B. H56-specific IgG binding response in 
groups primed with H56 + CAF01 and boosted with H56 + o/w 
squalene or with H56 alone was of 732 and 700 RU respectively, 
while the group boosted with CAF01 showed a lower RU (190), 
even if it was significantly higher compared to the corresponding 
group primed with H56 alone (P ≤ 0.05). The dissociation kinetic 
rates (koff) calculated for each curve did not show significant 
differences among the differently immunized groups (Figure S2B 
in Supplementary Material) and were similar to the koff value 
of a monoclonal anti-H56 antibody (Hyb76-8) used as reference 
(Figure S2A in Supplementary Material).
The analysis of the humoral response again confirms the 
importance of the correct combination of vaccine formulations 
to be used for priming and boosting, and strengthens the impor-
tance of the presence of the CAF01 adjuvant in the formulation 
used for priming rather than for boosting, in line with the cellular 
data.
DiscUssiOn
Heterologous prime-boost combinations including two differ-
ent vaccine adjuvants were used to study the role of the CAF01 
adjuvant in generating primary immune response. The analysis 
of the secondary antigen-specific immune response upon booster 
immunization has been instrumental for evaluating (i) the impact 
of the priming and boosting events on the immune response 
to vaccination, (ii) the role of the adjuvant component in the 
FigUre 3 | Intracellular cytokines production. C57BL/6 mice were subcutaneously immunized as summarized in Figure 1. Spleens were collected 7 and 28 days 
after priming, and 3 and 10 days after boosting. Splenocytes were restimulated for 6 h with H56 protein. (a) Dot plots showing the production of TNF-α, IFN-γ, 
IL-17, IL-4/IL-13 versus IL-2 assessed on live CD4+ CD44+ lymphocytes in each group, collected 10 days after boosting. (B) Percentages of T cells positive for both 
IL-2 and the indicated cytokines, with respect to total CD4+ CD44+ cells, elicited by different vaccine formulations reported as mean ± SEM of five mice per group. 
Mann–Whitney test for multiple pairwise comparisons was used for assessing statistical difference between groups receiving the same booster and primed with H56 
alone or H56 + CAF01 adjuvant. Kruskal–Wallis test, followed by Dunn’s post test for multiple comparison, was used to assess statistical difference among all 
groups (P ≤ 0.05).
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FigUre 4 | Computational analysis of polyfunctional profiles of T cells. C57BL/6 mice were subcutaneously immunized as summarized in Figure 1. CD4+ and 
CD44+ cells from restimulated splenocytes were manually gated with FlowJov10, concatenated within the same immunization group, randomly downsampled to 
15,000 cells and exported as uncompensated cells. Data were then compensated, logically transformed, and scaled with FlowSOM. A minimal spanning tree was 
obtained from the flowSet including FCS files of the groups primed with H56 + CAF01 and boosted with H56, H56 + CAF01, and H56 + o/w squalene. Size of the 
nodes is relative to the percentage of cells present in each cluster. Each node is represented by a star chart indicating the relative mean fluorescence intensity values 
of each cytokine; the height of each sector indicates the intensity, if the part reaches the border of the circle, the cells have maximal expression for that cytokine. A 
relative increase (blue nodes) or decrease (pink nodes) of at least twofold of the cell percentage in nodes of the CAF/CAF (a) or CAF/SQL (B) groups compared with 
the CAF/H56 group is shown. A magnification or colored nodes, indicated by numbers, is reported on the right.
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primary and booster immunization, and (iii) the impact of the 
vaccine formulation on the functional profile of the cellular 
response elicited.
The prime-boost study reported here demonstrates that a 
primary immunization performed with the vaccine antigen 
and the CAF01 adjuvant deeply impacts the immune response 
FigUre 5 | Comparison of FlowSOM clustering in different prime-boost combinations. Scatter plots showing the frequency of cells within the 49 nodes obtained 
with the FlowSOM analysis. Groups with the same priming and different boost are shown in (a,B) (CAF/CAF versus CAF/H56, CAF/SQL versus CAF/H56, 
respectively); groups with the same boost and different priming are shown in (c,D) (CAF/CAF versus H56/CAF and CAF/SQL versus H56/SQL, respectively). Each 
dot represents a node, and the X and Y axis report the percentage of cells clustered into this node calculated in the indicated prime-boost combination. Within the 
dashed lines are reported nodes (black) with a similar frequency of cells assessed in the two immunization combinations; nodes with a frequency of cells >2-fold 
with respect to the other immunization group are reported in blue or red. The threshold value was chosen according to default threshold in FlowSOM package. The 
number of nodes is reported in each sector.
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of the host, generating T and B cells capable of responding to 
recall immunization also when it is performed with the vaccine 
antigen alone. On the contrary, when the H56 vaccine antigen 
alone is used for priming, the secondary T immune response is 
completely abolished by the booster immunization, even in the 
presence of formulations including two potent adjuvants, such 
as CAF01 or o/w squalene, and the serum humoral response is 
much lower. The properties of these two adjuvants in eliciting an 
H56-specific primary immune response, have been previously 
characterized by our group (4). We demonstrated that the CAF01 
adjuvant promotes a Th1 and Th17 primary immune response, 
stimulates the GC reaction inside the draining lymph nodes, and 
promotes a slower response in terms of early serum antibodies 
compared to other adjuvants, probably due to its mechanism 
of action that entraps the antigen slowing down its release. The 
o/w squalene adjuvant stimulates a primary cellular response 
characterized by the release of TNF-α, IFN-γ, and IL-4/IL-13 
indicative of a mixed Th1/Th2 response, and elicits a rapid and 
significant humoral response in serum (4). The mixed combina-
tion of CAF01 for priming and o/w squalene for boosting tested 
here was extremely immunogenic both in terms of cellular and 
humoral response. A reactivation of the H56-specfic T helper 
response was elicited into the draining lymph nodes, and the 
effector function of reactivated cells reflected the profile elicited 
by the priming event, as shown by the production of TNF-α, 
IFN-γ, IL-2, and IL-17. Nevertheless, at the same time, there was 
a significant increase also of cells producing the cytokines IL-4 
and IL-13, that were not elicited by the priming with CAF01, but 
were observed in mice primed with o/w squalene adjuvant (4). 
As shown by the computational analysis of cytokine production, 
cells expressing IL-4/IL-13 produced also TNF-α, IFN-γ, and 
IL-2. The analysis of the secondary immune response elicited in 
the group primed with H56 + CAF01 demonstrated that the use 
of the antigen alone for booster immunization was extremely 
efficient. In this case, there was a significant reactivation of the 
T helper response, also in terms of effector cells. We observed 
that antigen alone stimulates the reactivation of cells releasing 
TNF-α, IFN-γ, and IL-2, but not high levels of IL-17, that was 
observed only in groups boosted with each of the adjuvanted 
formulations.
The induction of cells secreting these cytokines is critical 
in the host immune response to M. tuberculosis. IFN-γ is cru-
cial for the activation of macrophages, which in turn inhibit 
M. tuberculosis growth via induction of inducible isoform of 
nitric oxide synthase and autophagy (26), while TNF-α promotes 
the formation of mature granulomas and also activates infected 
FigUre 6 | Antigen-specific IgG response. C57BL/6 mice were subcutaneously immunized as summarized in Figure 1. H56-specific IgG serum titers were 
analyzed on day 0, 12, 28, 31, and 38 following priming, by enzyme-linked immunosorbent assay. Antibody titers are expressed as the reciprocal of the highest 
serum dilution with an OD value ≥0.2 after subtraction of background value (diluent buffer). Values are reported as geometric mean titers (GMT) ± 95% CI of 8–10 
mice per group from two independent experiments. Mann-Whitney test for multiple pairwise comparisons was used for assessing statistical difference between 
groups receiving the same booster and primed with H56 alone or H56 + CAF01 adjuvant, #P ≤ 0.05. Kruskal–Wallis test, followed by Dunn’s post test for multiple 
comparison, was used to assess statistical difference between all groups. *P ≤ 0.05.
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macrophages. IL-2 stimulates the expansion and maintenance of 
the T cell responses, therefore contributes to the host defense, 
and loss of IL-2-producing CD4+ T cells is associated with loss 
of protection (27). The requirement for cells producing IL-17 to 
control the pathogen is less absolute, even if vaccine promoted 
Th17 cells can improve mycobacterial control in animal models, 
promoting early Th1  cell recruitment to the lung following 
aerosol M. tuberculosis infection and reduce bacterial burden 
(28, 29).
The H56-specific humoral response was induced by formula-
tions containing the antigen alone or combined with adjuvants, 
with higher antibody titers observed in mice primed with H56 
+ CAF01 and boosted with H56 + o/w Squalene, or with H56 
alone. The latter formulations also elicited antibodies with the 
highest binding properties for the vaccine antigen. The analysis 
performed in the groups primed with H56 alone showed that 
also in the presence of adjuvants in the booster immunization, 
the secondary antibody response was lower, with a very low 
binding capacity to the vaccine antigen. Previous studies have 
shown a complete absence of GC B and follicular T helper 
cells when the primary immunization was performed with 
antigen alone, while short-lived plasma cells were induced (4). 
Interaction of Tfh cells with B cells drives the GC reaction, a 
dynamic micro-anatomical structure that supports the genera-
tion of B-cell activation, antibody class switch recombination, 
and affinity maturation (30, 31). The lack of the GC reaction, 
together with the induction of short-lived plasma cells capable 
of secreting low affinity antibodies (32), can explain the quality 
and the quantity of the humoral secondary response observed 
in mice primed with H56 alone. To note, a completely opposite 
result in terms of vaccine antigen binding capacity was obtained 
in mice primed with H56 and boosted with the H56 + CAF01, 
versus mice primed with the H56 + CAF01 and then boosted 
with the H56 alone.
The strong difference between the impact of the priming and 
boosting event on the immune response was clearly visualized 
with the computational analysis of the cytokine profile of reacti-
vated CD4+ T cells. The use of software capable of managing the 
huge amount of data produced by flow cytometry for each cell 
has become a necessity. Multiparametric data can no longer be 
adequately analyzed using the classical, mostly manual, analysis 
techniques, in which two parameters are combined in two-
dimensional scatterplots, and therefore require the use of novel 
computational techniques (23). Among many softwares now 
available (33), we employed the FlowSOM software (9), which 
is a platform of analysis available as an open-source package for 
R, an open-source environment for statistical analysis, computa-
tion, and visualization. A SOM is an unsupervised technique for 
clustering and dimensionality reduction, in which a discretized 
representation of the input space is trained. The graphical output 
generated is helpful for visually displaying T cell polyfunctional-
ity. This analysis clearly allowed to visualize a clusterization of 
cells producing different patterns of cytokines and to compare 
the polyfunctional activity of CD4+ T cells elicited by the different 
prime-boost combinations. Six different clusters were observed 
among groups primed with the CAF01 adjuvant and boosted 
with the same formulation, or with the o/w squalene adjuvant or 
with the vaccine antigen alone. Both adjuvants used for boost-
ing increased the amount of cells producing IL-17 together with 
TNF-α, IL-2, and IFN-γ, while only o/w squalene increased the 
frequency of cells co-expressing also IL-4 and IL-13. This analysis 
highlighted that also in the presence of the antigen alone we could 
FigUre 7 | Surface plasmon resonance analysis of H56-specific sera. A 
Biacore assay was performed on sera collected 10 days after booster 
immunization. Sera were diluted 200-fold and injected over H56 previously 
immobilized on CM4 sensor chip. (a) Sensorgrams of H56-specific antibodies 
binding (RU) from sera of single animals primed with the CAF01 adjuvant (blue 
lines) or with H6 alone (dashed lines). (B) Mean RU values ± SEM of five sera for 
group; filled bars indicate groups primed with CAF01 adjuvant, open bars with 
antigen alone. Mann–Whitney test for multiple pairwise comparisons was used 
for assessing statistical difference between groups receiving the same booster 
and primed with H56 alone or H56 + CAF01 adjuvant, #P ≤ 0.05. Kruskal–Wallis 
test, followed by Dunn’s post test for multiple comparison, was used to assess 
statistical difference between all groups. **P ≤ 0.01.
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reactivate a polyfunctional response, but the use of the adjuvant 
can be instrumental for modulating a specific type of effector 
cells. The number of clusters significantly different between 
groups primed with or without the CAF01 adjuvant, and boosted 
with the same formulation increased to 42, confirming again that 
the priming formulation defines the generation of cells capable of 
secondary reactivation.
The role of vaccine-induced polyfunctional CD4+ T cells in 
the protection from M. tuberculosis infection is not completely 
clear, and results obtained in preclinical and clinical stud-
ies are sometimes contradictory (34). In the mouse model, 
the magnitude of polyfunctional CD4+ T  cells often cor-
relates with vaccine-induced protection, generally assessed 
as vaccine-induced control of bacterial replication following 
challenge, thus making polyfunctional T  cells a good can-
didate for a mechanistic correlate of protection (34). It has 
been demonstrated that immunity elicited by H56 +  CAF01 
vaccination is associated with the maintenance of circulating 
polyfunctional CD4 T  cells, that selectively home to the lung 
parenchyma, and confer durable protection (35). It is likely 
that cells expressing multiple effector functions may be more 
effective in controlling infection than those producing a 
single pro-inflammatory cytokine. Nevertheless, in humans, 
same cases have been reported in which there was a progress 
to disease, also in the presence of a strong Th1 responses 
(25, 28), and very little data on the role of IL-17 are available 
(36). Taken together, polyfunctional CD4+ T cells deserve to be 
assessed and characterized, but other functional immunological 
components, including the humoral responses (37) should be 
analyzed and considered when assessing vaccine candidates to 
M. tuberculosis (38).
The data from the current study in mice emphasizes the role 
of adjuvant for the priming of an optimal immune response, 
whereas the adjuvant seems to be of less importance during 
the boosting. In particular, CAF01 seems to have the ability to 
prime a response that results in a qualitatively and quantitatively 
superior antibody response. Ongoing clinical trials with CAF01 
adjuvanted priming vaccines will soon demonstrate if these 
data can be translated into humans. If we in the future should 
implement heterologous immunization protocols in humans 
will eventually rely not only on immunogenicity but also on a 
number of practical considerations of great importance for vac-
cine implementation.
In conclusion, the primary stimulation of the immune system 
is crucial for the generation of cells capable of a recall response. 
The choice of an immunogenic vaccine formulation for priming 
event paves the path for the subsequent secondary response, 
while the choice of the formulation for boosting can be a tool for 
modulating the quality, more than the quantity, of the secondary 
response. The heterologous prime-boost approach for vaccina-
tion appears as an excellent strategy for the generation of vaccines 
specifically designed for specific pathogens.
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